You are here

Study Evaluating GAP-486 in Non-Sustained Ventricular Tachycardia

Last updated on December 15, 2017

FOR MORE INFORMATION
Study Location
Merced, California, 95340 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Arrhythmias
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18+ years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Male and female patients, 18 years of age or older, that have experienced an acute
ischemic event within 24 hours prior to study entry.

- Patients with a documented history of coronary artery disease or left ventricular
dysfunction

- Patients who have experienced an episode of non-sustained ventricular tachycardia
within 24 hours of the index ischemic event

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Patients who have had percutaneous coronary intervention (PCI), thrombolytics, or
open-heart surgery within 48 hours prior to study entry, or who require it during test
article administration

- Patients who have taken another antiarrhythmic medication (other than a beta blocker)
within 5 half-lives of the start of test article

- Patients who have a history of torsades de pointes, long QT syndrome, QTc > 0.50

NCT00124891
Pfizer
Terminated
Study Evaluating GAP-486 in Non-Sustained Ventricular Tachycardia

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Arrhythmias
NCT00124891
All Genders
18+
Years
Multiple Sites
Study Evaluating GAP-486 in Non-Sustained Ventricular Tachycardia
Study Evaluating Subjects With Non-Sustained Ventricular Tachycardia
To determine whether the administration of test article will decrease the occurrence of ventricular arrhythmias in patients who have acute coronary syndrome (unstable angina, ST segment elevated myocardial infarction or myocardial infarction without ST elevation).
Not Provided
Interventional
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Prevention
Arrhythmias
  • Drug: Double-blind investigational anti-arrhythmic
  • Drug: GAP-486
Not Provided
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
500
November 2006
Not Provided

INCLUSION CRITERIA:

  • Male and female patients, 18 years of age or older, that have experienced an acute ischemic event within 24 hours prior to study entry.
  • Patients with a documented history of coronary artery disease or left ventricular dysfunction
  • Patients who have experienced an episode of non-sustained ventricular tachycardia within 24 hours of the index ischemic event

EXCLUSION CRITERIA:

  • Patients who have had percutaneous coronary intervention (PCI), thrombolytics, or open-heart surgery within 48 hours prior to study entry, or who require it during test article administration
  • Patients who have taken another antiarrhythmic medication (other than a beta blocker) within 5 half-lives of the start of test article
  • Patients who have a history of torsades de pointes, long QT syndrome, QTc > 0.50
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Brazil,   Canada,   Croatia,   Denmark,   Former Serbia and Montenegro,   Hungary,   India,   Italy,   Mexico,   Poland,   Romania,   Russian Federation,   Sweden,   Ukraine,   United Kingdom,   United States
Serbia
 
NCT00124891
3163K1-200
Not Provided
Not Provided
Not Provided
Not Provided
Wyeth is now a wholly owned subsidiary of Pfizer
Not Provided
Study Director: Medical Monitor, MD Wyeth is now a wholly owned subsidiary of Pfizer
Principal Investigator: Trial Manager For Brazil, [email protected]
Principal Investigator: Trial Manager For Poland, [email protected]
Principal Investigator: Trial Manager For Romania and Russia, [email protected]
Principal Investigator: Trial Manager For Mexico, [email protected]
Principal Investigator: Trial Manager For Italy, [email protected]
Principal Investigator: Trial Manager For Hungary, [email protected]
Principal Investigator: Trial Manager For United Kingdom, [email protected]
Principal Investigator: Trial Manager For Sweden and Denmark, [email protected]
Wyeth is now a wholly owned subsidiary of Pfizer
December 2007

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now